Article citationsMore>>

Salazar, J., Navarro, C., Ortega, á., Nava, M., Morillo, D., Torres, W., Hernández, M., et al. (2021) Advanced Glycation End Products: New Clinical and Molecular Perspectives. International Journal of Environmental Research and Public Health, 18, Article No. 7236.
https://doi.org/10.3390/ijerph18147236

has been cited by the following article:

• TITLE: Antidiabetic Properties of Bidens pilosa and Its Polyacetylenic Compounds for Management of Diabetes: Systematic Review

  AUTHORS: Kenneth Waititu, Caroline Mugo, Daisy Nyawira, Peter Mwethera

  KEYWORDS: Antidiabetic, Cytopiloyne, Bidens pilosa, Polyacetylenic Compounds

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 8, 2024

  ABSTRACT: Bidens pilosa is a member of the Asteraceae family that is widely distributed across the tropics. It has been utilized by different communities both as food and medicinal herb. This plant and its polyacetylenic compounds hold potential as a natural antidiabetic intervention that can be used to combat this global public health problem. Bioactive compounds found in this plant constitute promising interventions for combating obesity which is a major risk factor for the development of type 2 diabetes. These phytocompounds can work independently or synergistically to modulate appetite, lipase activity, adipogenesis and adipocyte apoptosis. However, the efficacy, mode of action and scope of management of diabetes by these compounds remains elusive. The current review aims to summarize data on efficacy in the management of diabetes, an antidiabetic candidate polyacetylenic compound and possible biological activities as an antidiabetic agent from the available literature. Much emphasis has been directed to cytopiloyne as a representative of polyacetylenic compounds extracted from Bidens pilosa and its activity on diabetic animal models. The majority of the studies conducted on animal models described antidiabetic mechanisms that range from hypoglycemic to secretagogue activity of cytopiloyne in a dose-dependent manner. A clinical trial pilot indicated improved glycemic control of Bidens pilosa formulation among diabetic patients in the study. Bidens pilosa and its compounds are highly potent antidiabetic agent(s) that should be graduated to an intervention for management of diabetes through pre-clinical and clinical trials to elucidate its efficacy and safety.